Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries

被引：26

作者：

Filipe, Ana da Silva ^{[1
]}

Sreenu, Vattipally ^{[1
]}

Hughes, Joseph ^{[1
]}

Aranday-Cortes, Elihu ^{[1
]}

Irving, William L. ^{[2
,3
]}

Foster, Graham R. ^{[4
]}

Agarwal, Kosh ^{[5
]}

Rosenberg, William ^{[6
]}

Macdonald, Douglas ^{[6
]}

Richardson, Paul ^{[7
]}

Aldersley, Mark A. ^{[8
]}

Wiselka, Martin ^{[9
]}

Ustianowski, Andrew ^{[10
]}

McLauchlan, John ^{[1
]}

Thomson, Emma C. ^{[1
]}

机构：

[1] Univ Glasgow, Ctr Virus Res, MRC, Sir Michael Stoker Bldg,Garscube Campus, Glasgow G61 1QH, Lanark, Scotland

[2] Nottingham Univ Hosp NHS Trust, NIHR Nottingham Biomed Res Ctr, Gastrointestinal & Liver Disorders Theme, Nottingham, England

[3] Univ Nottingham, Nottingham, England

[4] Queen Mary Univ London, Blizard Inst, London, England

[5] Kings Coll Hosp Fdn Trust, Inst Liver Studies, London, England

[6] UCL, Inst Liver & Digest Hlth, London, England

[7] Royal Liverpool Univ NHS Trust, Liverpool, Merseyside, England

[8] St James Univ Hosp, Liver Unit, Leeds, W Yorkshire, England

[9] Univ Hosp Leicester NHS Trust, Infect Dis Unit, Leicester, Leics, England

[10] North Manchester Gen Hosp, Infect Dis, Manchester, Lancs, England

来源：

JOURNAL OF HEPATOLOGY | 2017年 / 67卷 / 06期

基金：

英国惠康基金; 英国医学研究理事会;

关键词：

HEPATITIS-C VIRUS; ACTING ANTIVIRAL THERAPY; DECOMPENSATED CIRRHOSIS; GENOTYPE; SOFOSBUVIR;

D O I：

10.1016/j.jhep.2017.06.035

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1348 / 1350

页数：4

共 10 条

[1] Ledipasvir Plus Sofosbuvir for 12 Weeks in Patients With Hepatitis C Genotype 4 Infection [J].

Abergel, Armand ;

Metivier, Sophie ;

Samuel, Didier ;

Jiang, Deyuan ;

Kersey, Kathryn ;

Pang, Phillip S. ;

Svarovskaia, Evguenia ;

Knox, Steven J. ;

Loustaud-Ratti, Veronique ;

Asselah, Tarik .

HEPATOLOGY, 2016, 64 (04) :1049-1056

[2] Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis [J].

Cheung, Michelle C. M. ;

Walker, Alex J. ;

Hudson, Benjamin E. ;

Verma, Suman ;

McLauchlan, John ;

Mutimer, David J. ;

Brown, Ashley ;

Gelson, William T. H. ;

MacDonald, Douglas C. ;

Agarwal, Kosh ;

Foster, Graham R. ;

Irving, William L. .

JOURNAL OF HEPATOLOGY, 2016, 65 (04) :741-747

[3] Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis [J].

Curry, M. P. ;

O'Leary, J. G. ;

Bzowej, N. ;

Muir, A. J. ;

Korenblat, K. M. ;

Fenkel, J. M. ;

Reddy, K. R. ;

Lawitz, E. ;

Flamm, S. L. ;

Schiano, T. ;

Teperman, L. ;

Fontana, R. ;

Schiff, E. ;

Fried, M. ;

Doehle, B. ;

An, D. ;

McNally, J. ;

Osinusi, A. ;

Brainard, D. M. ;

McHutchison, J. G. ;

Brown, R. S., Jr. ;

Charlton, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (27) :2618-2628

[4] EASL Recommendations on Treatment of Hepatitis C 2016 [J].

European Association for the Study of the Liver easloffice@easloffice.eu .

JOURNAL OF HEPATOLOGY, 2017, 66 (01) :153-194

[5] Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis [J].

Foster, Graham R. ;

Irving, William L. ;

Cheung, Michelle C. M. ;

Walker, Alex J. ;

Hudson, Benjamin E. ;

Verma, Suman ;

McLauchlan, John ;

Mutimer, David J. ;

Brown, Ashley ;

Gelson, William T. H. ;

MacDonald, Douglas C. ;

Agarwal, Kosh .

JOURNAL OF HEPATOLOGY, 2016, 64 (06) :1224-1231

[6] Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy [J].

Hedskog, C. ;

Dvory-Sobol, H. ;

Gontcharova, V. ;

Martin, R. ;

Ouyang, W. ;

Han, B. ;

Gane, E. J. ;

Brainard, D. ;

Hyland, R. H. ;

Miller, M. D. ;

Mo, H. ;

Svarovskaia, E. .

JOURNAL OF VIRAL HEPATITIS, 2015, 22 (11) :871-881

[7] Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus [J].

Lam, Angela M. ;

Espiritu, Christine ;

Bansal, Shalini ;

Steuer, Holly M. Micolochick ;

Niu, Congrong ;

Zennou, Veronique ;

Keilman, Meg ;

Zhu, Yuao ;

Lan, Shuiyun ;

Otto, Michael J. ;

Furman, Phillip A. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (06) :3359-3368

[8] Characterization of full-length hepatitis C virus sequences for subtypes 1e, 1h and 1l, and a novel variant revealed Cameroon as an area in origin for genotype 1 [J].

Li, Chunhua ;

Njouom, Richard ;

Pepin, Jacques ;

Nakano, Tatsunori ;

Bennett, Phil ;

Pybus, Oliver G. ;

Lu, Ling .

JOURNAL OF GENERAL VIROLOGY, 2013, 94 :1780-1790

[9] Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir [J].

Wyles, David ;

Dvory-Sobol, Hadas ;

Svarovskaia, Evguenia S. ;

Doehle, Brian P. ;

Martin, Ross ;

Afdhal, Nezam H. ;

Kowdley, Kris V. ;

Lawitz, Eric ;

Brainard, Diana M. ;

Miller, Michael D. ;

Mo, Hongmei ;

Gane, Edward J. .

JOURNAL OF HEPATOLOGY, 2017, 66 (04) :703-710

[10] NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome [J].

Zeuzem, Stefan ;

Mizokami, Masashi ;

Pianko, Stephen ;

Mangia, Alessandra ;

Han, Kwang-Hyub ;

Martin, Ross ;

Svarovskaia, Evguenia ;

Dvory-Sobol, Hadas ;

Doehle, Brian ;

Hedskog, Charlotte ;

Yun, Chohee ;

Brainard, Diana M. ;

Knox, Steven ;

McHutchison, John G. ;

Miller, Michael D. ;

Mo, Hongmei ;

Chuang, Wan-Long ;

Jacobson, Ira ;

Dore, Gregory J. ;

Sulkowski, Mark .

JOURNAL OF HEPATOLOGY, 2017, 66 (05) :910-918

← 1 →